Reaction

Application Site Discolouration reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,019 reports · 44 co-occurring drugs

As of the last recalculation, Application Site Discolouration appears in 4,019 FAERS reports alongside 44 co-occurring drug terms. The strongest observed disproportionality signal is GLYCERIN, LIDOCAINE (PRR 30.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Glycerin, Lidocaine	81	30.6	30.7
Docosanol	81	29.2	29.3
Buprenorphine	402	24.9	25.0
Methylphenidate	110	20.2	20.3
Tretinoin	29	18.6	18.7
Crisaborole	32	17.4	17.5
Nicotine	123	16.2	16.3
Oxybutynin	81	14.6	14.6
Rotigotine	33	11.9	11.9
Minocycline	23	10.3	10.3
Dapsone	18	8.8	8.8
Estradiol	140	8.7	8.7
Nicotine Polacrilex Mini	19	6.6	6.6
Nicotine Polarilex	19	6.6	6.6
Clobetasol Propionate Ointment Usp, 0.05%	12	6.0	6.1
Minoxidil	48	5.6	5.6
Rivastigmine	20	5.5	5.5
Granisetron	11	5.4	5.4
Minoxidil Foam 5% (Womens)	33	5.2	5.2
Nicotine Polacrilex	37	5.0	5.0
Progesterone	21	4.8	4.8
Bimatoprost	25	4.5	4.5
Mupirocin	11	4.2	4.2
Triamcinolone Acetonide Ointment Usp, 0.05%	19	4.2	4.2
Mupirocin Calcium	11	4.2	4.2
Clobetasol Propionate	8	4.0	4.0
Clonidine	39	4.0	4.0
Ketoconazole Cream, 2%	11	3.8	3.8
Diclofenac Potassium	8	3.8	3.8
Sumatriptan	27	3.7	3.7
Rizatriptan Benzoate	7	3.6	3.6
Estradiol Gel 0.1%	30	3.5	3.5
Estradiol Transdermal	30	3.5	3.5
Thyroid, Porcine	7	3.4	3.4
Pegfilgrastim	61	3.2	3.2
Triamcinolone Acetonide	19	3.2	3.2
Miconazole Nitrate	5	3.0	3.0
Sumatriptan Succinate	14	2.9	2.9
Insulin Glulisine	5	2.5	2.5
Alpelisib	3	1.8	1.8
Tapentadol Hydrochloride	6	0.9	0.9
Guselkumab	5	0.7	0.7
Salicylic Acid	5	0.5	0.5
Adapalene	6	0.2	0.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.